SUMMARY: The Administration for Children and Families (ACF), Administration for Native Americans (ANA) announces the award of a single source emergency grant in the amount of $400,000 to the Oglala Sioux Tribe to provide empowerment activities for youth in order to address the critically high levels of youth suicide on the reservation since December 2014.

DATES: The timeframe for the initial award is July 31, 2015 to July 30, 2016.

FOR FURTHER INFORMATION CONTACT: Carmelia Strickland, Director, Division of Program Operations, Administration for Native Americans, 370 L’Enfant Promenade SW., Washington, DC 20047. Telephone: 877–922–9262; Email: Carmelia.strickland@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: The Administration for Native Americans (ANA), Administration for Children and Families, has awarded an emergency single source grant to the Oglala Sioux Tribe (OST) for programs whose goal is to empower youth ages 8 to 24 to make changes in their communities, to be proud of their heritage, and to inspire them to celebrate life so that they may see that there is a positive future for them. It is intended that this program will have a 24-month project period so that another 12-month budget period will be funded noncompetitively for $400,000 in FY 2016. In testimony before the Senate Committee on Indian Affairs on June 24, 2015, Oglala Sioux Tribe President John Yellowbird Steele’s testimony stated that 11 young people on the Pine Ridge Reservation have been lost to suicide since December. In addition, at least another 176 of the youth have attempted suicide in that period, according to the Indian Health Service, and 229 more were treated for suicidal ideation.

The awarded project is designed to increase positive youth empowerment activities in all nine districts on the Pine Ridge Indian Reservation through the development of Student Youth Councils, peer to peer mentoring, and Lakota cultural awareness activities. The award was made under ANA’s program for Social and Economic Development Strategies (SEDS). The OST has been designated as a Federal government Promise Zone, because of the severe financial and economic status in the area in which they live. The Pine Ridge Reservation is also located in Shannon County, which is often referred to as the poorest county in the United States.

Statutory Authority: This program is authorized under § 803(a) of the Native American Programs Act of 1974 (NAPA), 42 U.S.C. 2991b.

Christopher Beach,
Senior Grants Policy Specialist, Division of Grants Policy, Office of Administration.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Native Americans

Delegation of Authority

Notice is hereby given that I have delegated to the Administrator of the Administration for Community Living, or his or her successor, the following authorities vested in the Secretary:

• The authorities vested under 42 U.S.C. 300d–52 and 300d–53, as amended by Sections 3 and 4 of the Traumatic Brain Injury Reauthorization Act of 2014 (P.L. 113–196), titled “State Grants for Projects Regarding Traumatic Brain Injury” and “State Grants for Protection and Advocacy Services.”

(Prior to the passage of the Traumatic Brain Injury Reauthorization Act of 2014, exercise of these authorities was vested by statute with the Administrator, Health Resources and Services Administration.) These authorities may be redelegated. This delegation excludes the authority to issue regulations, to establish advisory committees and councils, and appoint their members, and to submit reports to Congress, and shall be exercised in accordance with the Department’s applicable policies, procedures, and guidelines. This delegation will concurrently supersede all existing delegations of these authorities.

I hereby affirm and ratify any actions taken by agency officials which involved the exercise of the authorities delegated herein prior to the effective date of this delegation.

This delegation is effective October 1, 2015.

Dated: August 31, 2015.
Sylvia M. Burwell,
Secretary.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2015–N–0007]

Fee for Using a Tropical Disease Priority Review Voucher in Fiscal Year 2016

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or the Agency) is announcing the fee rates for using a
tropical disease priority review voucher for fiscal year (FY) 2016. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Food and Drug Administration Amendments Act of 2007 (FDAAA), authorizes FDA to determine and collect priority review user fees for certain applications for approval of drug or biological products when those applications use a tropical disease priority review voucher awarded by the Secretary of Health and Human Services. These vouchers are awarded to the sponsors of certain tropical disease product applications, submitted after September 27, 2007, upon FDA approval of such applications. The amount of the fee submitted to FDA with applications using a tropical disease priority review voucher is determined each fiscal year based on the difference between the average cost incurred by FDA in the review of a human drug application subject to priority review in the previous fiscal year, and the average cost incurred in the review of an application that is not subject to priority review in the previous fiscal year. This notice establishes the tropical disease priority review fee rate for FY 2016.

FOR FURTHER INFORMATION CONTACT:

SUPPLEMENTARY INFORMATION:

I. Background

Section 1102 of FDAAA (Pub. L. 110–85) added section 524 to the FD&C Act (21 U.S.C. 360j). In section 524, Congress encouraged development of new drug and biological products for prevention and treatment of certain tropical diseases by offering additional incentives for obtaining FDA approval of such products. Under section 524, the sponsor of an eligible human drug application submitted after September 27, 2007, for a qualified tropical disease (as defined in section 524(a)(3) of the FD&C Act), shall receive a priority review voucher upon approval of the tropical disease product application. The recipient of a tropical disease priority review voucher may either use the voucher with a future submission to FDA under section 505(b)(1) of the FD&C Act (21 U.S.C. 355(b)(1)) or section 351 of the Public Health Service Act (42 U.S.C. 262), or transfer (including by sale) the voucher to another party that may then use it. A priority review is a review conducted with a Prescription Drug User Fee Act (PDUFA) goal date of 6 months after the receipt or filing date, depending upon the type of application. Information regarding the PDUFA goals is available at: http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf.

The application that uses a priority review voucher is entitled to a priority review but must pay FDA a priority review user fee in addition to any other fee required by PDUFA. FDA published a draft guidance on its Web site about how this tropical disease priority review voucher program operates (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080559.pdf).

This notice establishes the tropical disease priority review fee rate for FY 2016 as $2,727,000 and outlines FDA’s process for implementing the collection of the priority review user fees. This rate is effective on October 1, 2015, and will remain in effect through September 30, 2016, for applications submitted with a tropical disease priority review voucher. The payment of this priority review user fee is required in addition to the payment of any other fee that would normally apply to such an application under PDUFA before FDA will consider the application complete and acceptable for filing.

II. Tropical Disease Priority Review User Fee for FY 2016

Under section 524(c)(2) of the FD&C Act, the amount of the tropical disease priority review user fee is determined each fiscal year based on the difference between the average cost incurred by FDA in the review of a human drug application subject to priority review in the previous fiscal year, and the average cost incurred by FDA in the review of a human drug application that is not subject to priority review in the previous fiscal year. The priority review voucher fee is intended to cover the incremental costs for FDA to do a priority review on a product that would otherwise get a standard review. The formula provides the Agency with the added resources to conduct a priority review while still ensuring a robust priority review voucher program that is consistent with the Agency’s public health goal of encouraging the development of new drug and biological products.

A priority review is a review conducted with a PDUFA goal date of 6 months after the receipt or filing date, depending upon the type of application. Under the PDUFA goal letter, FDA has committed to reviewing and acting on 90 percent of the applications granted priority review status within this expedited timeframe. Normally, an application for a human drug or biological product will qualify for priority review if the product is intended to treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. An application that does not receive a priority designation will receive a standard review. Under the PDUFA goals letter, FDA committed to reviewing and acting on 90 percent of standard applications within 10 months of the receipt or filing date, depending upon the type of application. A priority review involves a more intensive level of effort and a higher level of resources than a standard review.

Section 524 of the FD&C Act specifies that the fee amount should be based on the difference between the average cost incurred by the Agency in the review of a human drug application subject to a priority review in the previous fiscal year, and the average cost incurred by FDA in the review of a human drug application that is not subject to priority review in the previous fiscal year. FDA is setting fees for FY 2016, and the previous fiscal year is FY 2015. However, the FY 2015 submission cohort has not been closed out yet, and the cost data for FY 2015 are not complete. The latest year for which FDA has complete cost data is FY 2014. Furthermore, because FDA has never tracked the cost of reviewing applications that get priority review as a separate cost subset, FDA estimated the cost based on other data that the Agency has tracked. FDA uses data that the Agency estimates and publishes on its Web site each year—standard costs for review. FDA does not publish a standard cost for “the review of a human drug application subject to priority review in the previous fiscal year.” However, we expect all such applications would contain clinical data. The standard cost application categories with clinical data that FDA does publish each year are: (1) New drug applications (NDAs) for a new molecular entity (NME) with clinical data and (2) biologics license applications (BLAs).

The worksheets for standard costs for FY 2014, show a standard cost (rounded to the nearest thousand dollars) of $5,646,000 for a NME NDA and $5,533,000 for a BLA. Based on these standard costs, the total cost to review the 48 applications in these two categories in FY 2014 (30 NME NDAs with clinical data and 18 BLAs) was $269,974,000. (Note: these numbers do not include the President’s Emergency Plan for AIDS Relief NDAs; no
investigational new drug review costs are included in this amount.) Twenty-nine of these applications (20 NDAs and 9 BLAs) received priority review, which would mean that the remaining 19 received standard reviews. Because a priority review compresses a review that ordinarily takes 10 months into 6 months, FDA estimates that a multiplier of 1.67 (10 months divided by 6 months) should be applied to non-priority review costs in estimating the effort and cost of a priority review as compared to a standard review. This multiplier is consistent with published research on this subject. In the article “Developing Drugs for Developing Countries,” published in “Health Affairs,” Volume 25, Number 2, in 2006, the comparison of historical average review times by David B. Ridley, Henry G. Grabowski, and Jeffrey L. Moe, supports a priority review multiplier in the range of 1.48 to 2.35. The multiplier derived by FDA falls well below the midpoint of this range. Using FY 2014 figures, the costs of a priority and standard review are estimated using the following formula: 

\[(29 \times 1.67) + (19 \times \alpha) = \text{total cost} \times \alpha \]

where “\(\alpha\)” is the cost of a standard review and “\(\alpha \times 1.67\)” is the cost of a priority review. Using this formula, the cost of a standard review for NME NDAs and BLAs is calculated to be $3,989,000 (rounded to the nearest thousand dollars) and the cost of a priority review for NME NDAs and BLAs is 1.67 times that amount, or $6,662,000 (rounded to the nearest thousand dollars). The difference between these two cost estimates, or $2,673,000, represents the incremental cost of conducting a priority review rather than a standard review.

For the FY 2016 fee, FDA will need to adjust the FY 2014 incremental cost by the average amount by which FDA’s average costs increased in the 3 years prior to FY 2015, to adjust the FY 2014 amount for cost increases in FY 2015. That adjustment, published in the Federal Register on August 3, 2015 (see 80 FR 46028 at 46029), setting FY 2016 PDUFA fees, is 2.066 percent for the most recent year, not compounded. Increasing the FY 2014 incremental priority review cost of $2,673,000 by 2.066 percent results in an estimated cost of $2,727,000 (rounded to the nearest thousand dollars). This is the priority review user fee amount for FY 2016 that must be submitted with a priority review voucher in FY 2016, in addition to any PDUFA fee that is required for such an application.

### III. Fee Schedule for FY 2016

The fee rate for FY 2016 is set out in table 1:

<table>
<thead>
<tr>
<th>Fee category</th>
<th>Fee rate for FY 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application submitted with a tropical disease priority review voucher in addition to the normal PDUFA fee</td>
<td>$2,727,000</td>
</tr>
</tbody>
</table>

### IV. Implementation of Tropical Disease Priority Review User Fee

Under section 524(c)(4)(A) of the FD&C Act, the priority review user fee is due upon submission of a human drug application for which the priority review voucher is used. Section 524(c)(4)(B) of the FD&C Act specifies that the application will be considered incomplete if the priority review user fee and all other applicable user fees are not paid in accordance with FDA payment procedures. In addition, FDA may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section of the FD&C Act and FDA may not collect priority review voucher fees prior to a relevant appropriation for fees for that fiscal year. Beginning with FDA’s appropriation for FY 2009, the annual appropriation language states specifically that “priority review user fees authorized by 21 U.S.C. 360n (section 524 of the FD&C Act) may be credited to this account, to remain available until expended.” (Pub. L. 111–8, Section 5, Division A, Title VI).

The tropical disease priority review fee established in the new fee schedule must be paid for any application that is received on or after October 1, 2015, and submitted with a priority review voucher. This fee must be paid in addition to any other fees due under PDUFA. Payment must be made in U.S. currency by check, bank draft, or U.S. postal money order payable to the order of the Food and Drug Administration. The user fee identification (ID) number should be included on the check, followed by the words “Tropical Disease Priority Review.” Payments can be mailed to: Food and Drug Administration, P.O. Box 7979107, St. Louis, MO 63197–9000.

If checks are sent by a courier that requests a street address, the courier can deliver the checks to: U.S. Bank, Attention: Government Lockbox 979107, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This U.S. Bank address is for courier delivery only.) The FDA post office box number (P.O. Box 979107) must be written on the check. The tax identification number of FDA is 53–0196965.

Wire transfer payments may also be used. Please reference your unique user fee ID number when completing your transfer. The originating financial institution may charge a wire transfer fee. Please ask your financial institution about the fee and include it with your payment to ensure that your fee is fully paid. The account information is as follows: New York Federal Reserve Bank, U.S. Dept. of Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Account Number: 75060099, Routing Number: 021030004, SWIFT: FRNYUS33, Beneficiary: FDA, 8455 Colesville Rd., Silver Spring, MD 20993–0002.

Dated: September 8, 2015.

Leslie Kux, Associate Commissioner for Policy.

[FR Doc. 2015–23006 Filed 9–11–15; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2015–N–0001]

Anesthetic and Analgesic Drug Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Anesthetic and Analgesic Drug Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on November 6, 2015, from 8 a.m. to 5 p.m.

Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993–0002.

Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/